Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program
One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Va
Read More
Home
Join us in redefining the future of nicotine dependence
We are a late-stage specialty pharmaceutical company dedicated to tackling the global nicotine dependence epidemic by advancing cytisinicline.
In September 2025, our New Drug Application, submitted to the FDA in June 2025, was accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026 for cytisinicline as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its fully enrolled open-label safety study.
If approved, cytisinicline has the potential to become the first new FDA-approved treatment option in nearly 20 years.
29M
Smokers in the US 1
17M
E-Cigs in the US 2
Nicotine dependence is a serious medical issue that demands a medical solution
The harms associated with smoking are well established, increasing the risk of COPD, cardiovascular disease, cancer, and other serious conditions.
While over half attempt to quit smoking each year, fewer than 10% succeed.1 The toll is staggering – lost lives and over $600 billion in annual smoking-related healthcare costs.14
A more effective treatment is critical to addressing this widespread public health crisis.
8M
Worldwide Deaths Annually4
16M
Americans Live with Smoking- Related Disease5
Introducing
Cytisinicline
demonstrated in clinical trials to provide favorable odds of quitting6,7
focused on precision targeting of nicotine receptors
In two recent trials, cytisinicline has been shown to effectively help even highly dependent smokers stop smoking.6,7 Cytisinicline binds to the same receptors as nicotine to reduce both withdrawal symptoms and satisfaction associated with smoking.8 And since it doesn’t bind as strongly to certain receptors, it is believed to have less potential to cause side effects — including nausea and vomiting.
Smoking cessation phase 3 trial results
vaping cessation phase 2 trial results
cytisinicline development program
Latest News
WE CAN’T HELP BUT
BELIEVE
And we’re looking for others, like us, who believe we can bring an end to this fight. Will you join us?
- US Headquarters
- 22722 29th Dr SE, Suite 100
- Bothell, WA 98021
- Phone: (425) 686-1500
- Vancouver Office
- 1040 W Georgia Street, Suite 1030
- Vancouver, BC V6E 4H1